Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Recombinant vaccinia virus-based vaccine combined with DNA vaccine has produced a protective immune response against HIV infection in non-human primates. In this study, we explored the immunogenicity of a recombinant vaccinia virus (LC16m8 strain), which has been used in children without severe side effects. The vaccinia virus expressing an HIV(89.6)env gene (vLC-Env) alone or combined with a DNA vaccine expressing the HIV(89.6)env gene (pCAG-Env) was characterized in BALB/c mice. Vaccination of vLC-Env induced much higher HIV-specific humoral and cell-mediated immune responses than that of pCAG-Env. Priming with pCAG-Env further enhanced vLC-Env induced immune responses, especially cell-mediated immune response. Moreover, efficient expression of Env protein was achieved following infection of bone marrow dendritic cells by vLC-Env in vitro. Administration of vLC-Env-infected dendritic cells to mice generated a high cell-mediated immune response. These results demonstrate that priming with pCAG-Env and boosting with vLC-Env represents a logical candidate for vaccination against HIV infection.
Shinoda
Kaori
K
Department of Molecular Biodefense Research, Yokohama City University School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan.
Xin
Ke-Qin
KQ
Kojima
Yoshitsugu
Y
Saha
Sukumar
S
Okuda
Kentaro
K
Okuda
Kenji
K
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism / Q000637:transplantation; D005260:Female; D015870:Gene Expression / Q000235:genetics; D015694:Gene Products, rev / Q000235:genetics / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology; D019302:HIV Envelope Protein gp160 / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology; D007117:Immunization, Secondary / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D011995:Recombination, Genetic; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014611:Vaccination / Q000379:methods; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics* / Q000276:immunology; D054321:rev Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015694:Gene Products, rev; D015699:HIV Envelope Protein gp120; D019302:HIV Envelope Protein gp160; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D054321:rev Gene Products, Human Immunodeficiency Virus; D007371:Interferon-gamma